Journal article
Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection
R Désert, F Rohart, F Canal, M Sicard, M Desille, S Renaud, B Turlin, P Bellaud, C Perret, B Clément, KA Lê Cao, O Musso
Hepatology | WILEY | Published : 2017
DOI: 10.1002/hep.29254
Abstract
Hepatocellular carcinomas (HCCs) exhibit a diversity of molecular phenotypes, raising major challenges in clinical management. HCCs detected by surveillance programs at an early stage are candidates for potentially curative therapies (local ablation, resection, or transplantation). In the long term, transplantation provides the lowest recurrence rates. Treatment allocation is based on tumor number, size, vascular invasion, performance status, functional liver reserve, and the prediction of early (<2 years) recurrence, which reflects the intrinsic aggressiveness of the tumor. Well-differentiated, potentially low-aggressiveness tumors form the heterogeneous molecular class of nonproliferative ..
View full abstractGrants
Awarded by Agence Nationale de la Recherche
Funding Acknowledgements
Supported by INSERM, Universite de Rennes 1, Region Bretagne (VALCIPRE), Agence Nationale de la Recherche (ANR-11-ISV1-0001), Institut National du Cancer (WntHCC), Fondation Recherche Medicale (ING20121226393), Ligue Nationale Contre le Cancer (Comite des Cotes d'Armor), Feder, Contrat de Plan Etat Region 2007-2013, and projet Canceropole.